(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/091764 Al 1 June 2017 (01.06.2017) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/352 (2006.01) A61K 31/192 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/US2016/063662 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 23 November 2016 (23.1 1.2016) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 62/259,549 24 November 2015 (24. 11.2015) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: CONSTANCE THERAPEUTICS, INC. kind of regional protection available): ARIPO (BW, GH, [US/US]; 506 Tremont Avenue, Point Richmond, Califor GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, nia 94801 (US). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (72) Inventors: FINLEY, Constance; c/o Constance Thera DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, peutics, Inc., 506 Tremont Avenue, Point Richmond, Cali LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, fornia 94801 (US). BESTWICK, Haley Poole; c/o Con SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, stance Therapeutics, Inc., 506 Tremont Avenue, Point GW, KM, ML, MR, NE, SN, TD, TG). Richmond, California 94801 (US). Published: (74) Agents: PRESLEY, Andrew D . et al; Kilpatrick Town- send and Stockton LLP, Two Embarcadero Center, Suite — with international search report (Art. 21(3)) 1900, San Francisco, California 941 11 (US). (54) Title: CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF MCF-7 FIG. 10A (57) Abstract: The present invention provides cannabis oil compositions, including cannabis oil compositions containing vitamin E, and methods for preparing the cannabis oil compositions. In some embodiments, the invention provides a method for preparing a cannabis oil composition comprising eluting cannabinoids from cannabis plant material with a solvent to produce an eluate; filtering the eluate with a filter to produce a filtrate; evaporating the solvent from the filtrate with a distiller to produce a distillate; and pur ging the distillate under conditions sufficient to remove residual solvent. In some embodiments, the method further includes mixing a quantity of vitamin E with the extract. Blended cannabis oil compositions containing mixtures of cannabis oil preparations are also described. CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF CROSS-REFERENCES TO RELATED APPLICATIONS [0001] The present application claims priority to U.S. Provisional Pat. Appl. No. 62/259,549, filed on November 24, 2015, which application is incorporated herein by reference in its entirety for all purposes. FIELD OF TECHNOLOGY [0002] This disclosure relates generally to cannabis oils and cannabis oil formulations, including cannabis oil compositions with vitamin E, and methods of preparation thereof. BACKGROUND OF THE INVENTION [0003] The medicinal use of oils and extracts derived from cannabis plant material has been growing in popularity. For example, pharmacologically active compounds in cannabis plant material including, but not limited to, delta-9-tetrahydrocannabinol (or THC) and cannabidiol (CBD) have been shown to reduce the effects of nausea and vomiting caused by certain chemotherapy treatments. Research has also shown the ability of cannabinoids and other compounds found in cannabis to stimulate bone growth, relieve pain, aid sleep, inhibit bacterial cell growth, inhibit cancer cell growth, and alleviate or otherwise reduce the symptoms of cancer, epilepsy, autoimmune disease, neurodegeneration, Alzheimer's disease, Lyme disease, post-traumatic stress disorder, and inflammation. Furthermore, extracts of cannabis plant material, whether ingested or inhaled, have also been shown to have therapeutic effects in patients with glaucoma, dysmenorrhea, migraines, anxiety disorders, or a combination thereof. [0004] However, cannabis oil is often highly viscous, making it difficult to work with and load into new delivery devices such as vaporizers and E-cigarettes. In addition, such oils, when vaporized or smoked, are often rough on a patient's throat and may induce coughing or gagging. [0005] Therefore, a solution is needed in order to make such extracts more conducive to today's delivery devices and make the inhalation/consumption of such extracts more palatable for patients. In addition, such a solution should also not have an adverse effect on the potency of the extract's active compounds and preserve the extract's gustatory or aromatic qualities. BRIEF SUMMARY OF THE INVENTION [0006] Disclosed herein are cannabis oil extracts, compositions containing blended mixtures of the extracts, and methods for preparing the extracts and compositions. In particular, a method is disclosed for preparing a cannabis oil composition comprising eluting cannabinoids from cannabis plant material with a solvent to produce an eluate, filtering the eluate with a filter to produce a filtrate, evaporating the solvent from the filtrate with a distiller to produce a distillate, and dehydrating/purging the distillate with a dehydrator or vacuum oven to produce an extract. In some embodiments, the method further includes mixing a quantity of vitamin E with the extract. In some embodiments, the quantity of vitamin E is sufficient to reduce the viscosity of the composition to less than 3500 cP. In some embodiments, the method includes eluting cannabinoids and terpenes from cannabis plant material to produce the eluate. In some embodiments, the method includes mixing the extract with essential oils. [0007] In certain embodiments, the invention provides a composition comprising a first cannabis oil preparation having a first cannabinoid profile and a second cannabis oil preparation having a second cannabinoid profile. In some embodiments, the composition comprises ∆ -tetrahydrocannabinol (THC) and (-)-cannabidiol (CBD). In some embodiments, the ratio of THC to CBD ranges from about 20: 1 to about 1:20 by weight. In some embodiments, the ratio of THC to CBD is about 4 :1 by weight. In some embodiments, the composition comprises one or more additional cannabis oils having additional cannabinoid profiles. [0008] The methods and compositions disclosed herein may be implemented in any means for achieving various aspects. Other features will be apparent from the accompanying drawings and from the detailed description that follows. BRIEF DESCRIPTION OF THE DRAWINGS [0009] Exemplary embodiments are illustrated by way of example and are not limited to the figures of the accompanying drawings, in which, like references indicate similar elements. [0010] Fig. 1A shows a method of preparing a cannabis oil composition according to one embodiment of the invention. [0011] Fig. IB shows a method of preparing a cannabis oil composition according to an embodiment of the invention including optional decarboxylation and filtration steps. [0012] Fig. 2 shows a graph depicting the viscosities of cannabis oil compositions as a function of vitamin E percentages in the cannabis oil compositions. [0013] Fig. 3 is a graph depicting THC and CBD percentages in cannabis oil compositions made from various strains of cannabis plant material. [0014] Fig. 4A shows the growth of SF-268 brain cancer cells in the presence of blended cannabis oil compositions and single-strain cannabis oil compositions. [0015] Fig. 4B shows the growth of SF-268 brain cancer cells in the presence THC and CBD at concentrations equal to the concentration in blended cannabis oil compositions and single-strain cannabis oil compositions. [0016] Fig. 4C shows the growth of SF-268 brain cancer cells in the presence of isolated cannabinoids. [0017] Fig. 5A shows the growth of SF-295 brain cancer cells in the presence of blended cannabis oil compositions and single-strain cannabis oil compositions. [0018] Fig. 5B shows the growth of SF-295 brain cancer cells in the presence THC and CBD at concentrations equal to the concentration in blended cannabis oil compositions and single-strain cannabis oil compositions. [0019] Fig. 5C shows the growth of SF-295 brain cancer cells in the presence of isolated cannabinoids. [0020] Fig. 6A shows the growth of SF-539 brain cancer cells in the presence of blended cannabis oil compositions and single-strain cannabis oil compositions. [0021] Fig. 6B shows the growth of SF-539 brain cancer cells in the presence THC and CBD at concentrations equal to the concentration in blended cannabis oil compositions and single-strain cannabis oil compositions. [0022] Fig. 6C shows the growth of SF-539 brain cancer cells in the presence of isolated cannabinoids. [0023] Fig. 7A shows the growth of SNB-19 brain cancer cells in the presence of blended cannabis oil compositions and single-strain cannabis oil compositions. [0024] Fig. 7B shows the growth of SNB-19 brain cancer cells in the presence THC and CBD at concentrations equal to the concentration in blended cannabis oil compositions and single-strain cannabis oil compositions. [0025] Fig. 7C shows the growth of SNB-19 brain cancer cells in the presence of isolated cannabinoids. [0026] Fig. 8A shows the growth of SNB-75 brain cancer cells in the presence of blended cannabis oil compositions and single-strain cannabis oil compositions.